Results 201 to 210 of about 20,940 (309)

BRD9 inhibition as potential treatment option for testicular germ cell tumors

open access: yesAndrology, EarlyView.
Abstract Background Testicular germ cell tumors (TGCT) are the predominant tumor in younger males. Usually, 5‐year survival rates are quite high, but 15–20% of patients with metastatic non‐seminomas are resistant to standard cisplatin‐based therapy.
Aylin Hansen   +5 more
wiley   +1 more source

Liposarcoma Arising From Mature Teratoma Following Testicular Tumor Surgery: A Case Report. [PDF]

open access: yesIJU Case Rep
Yamazaki M   +8 more
europepmc   +1 more source

Semen quality in patients with testicular cancer is associated with age and with greatly elevated levels of beta human chorionic gonadotropin

open access: yesAndrology, EarlyView.
Abstract Background Poor semen quality is a well‐known feature in patients with testicular germ cell tumours (GCTs) at the time of diagnosis but the underlying biological reasons are incompletely understood. Objectives This study aimed to identify GCT‐specific clinical factors that are involved with poor semen quality in GCT patients.
Klaus‐Peter Dieckmann   +9 more
wiley   +1 more source

Expression and therapeutic potential of TROP2 in cisplatin-resistant germ cell tumors. [PDF]

open access: yesJ Cancer Res Clin Oncol
Sperber L   +12 more
europepmc   +1 more source

CRISPR/Cas9‐mediated Genome‐editing Reveals 10 Testis‐enriched Genes and One Non‐testis‐enriched Gene are Dispensable for Male Fecundity in Mice

open access: yesAndrology, EarlyView.
ABSTRACT Background More than 1000 genes have been identified as predominantly expressed in the human testis. Advances in gene editing technologies have enabled the rapid and efficient generation of genetically engineered mice. This approach facilitates the screening of genes essential for spermatogenesis by analyzing knockout mouse models.
Yumiao Qiu   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy